Claus Garbe

Claus Garbe's AcademicInfluence.com Rankings

Claus Garbe

Computer Science

#3228

World Rank

#3382

Historical Rank

Computational Linguistics

#132

World Rank

#135

Historical Rank

Machine Learning

#330

World Rank

#334

Historical Rank

Artificial Intelligence

#520

World Rank

#529

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Claus Garbe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claus Garbe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014) (1716)
Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) (1601)
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) (1230)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. (2016) (712)
Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. (2008) (696)
Dermcidin: a novel human antibiotic peptide secreted by sweat glands (2001) (692)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) (681)
Melanoma epidemiology and trends. (2009) (638)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. (2016) (528)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects (2011) (519)
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. (2016) (505)
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. (2003) (490)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. (2016) (467)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab (2016) (442)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (2017) (426)
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. (2012) (420)
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. (2015) (416)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. (2010) (375)
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. (2015) (374)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
Improving Melanoma Classification by Integrating Genetic and Morphologic Features (2008) (354)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. (2003) (326)
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. (2008) (315)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. (2002) (303)
Metastatic pathways and time courses in the orderly progression of cutaneous melanoma (2002) (288)
Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. (1994) (278)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (276)
Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients (2009) (274)
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. (2003) (263)
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. (2005) (262)
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. (2019) (258)
Deficiency of Dermcidin-Derived Antimicrobial Peptides in Sweat of Patients with Atopic Dermatitis Correlates with an Impaired Innate Defense of Human Skin In Vivo1 (2005) (251)
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. (2015) (250)
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. (2014) (246)
The natural course of cutaneous melanoma (2004) (240)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
Human melanoma progression in skin reconstructs : biological significance of bFGF. (2000) (228)
Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients (2000) (222)
Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients (1995) (220)
Age and gender are significant independent predictors of survival in primary cutaneous melanoma (2008) (219)
Epidemiology of Cutaneous Melanoma in Germany and Worldwide (2001) (215)
Diagnosis and treatment of cutaneous melanoma: state of the art 2006. (2007) (212)
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA (2008) (211)
Primary cutaneous melanoma. Prognostic classification of anatomic location (1995) (211)
Basal cell carcinoma: histological classification and body‐site distribution (2006) (207)
Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. (1991) (207)
Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. (1998) (206)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells (2013) (198)
The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. (2003) (196)
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma (2015) (191)
Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. (2003) (188)
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. (2000) (183)
Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. (1994) (176)
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. (2007) (176)
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases (2003) (174)
Epidemiology of skin cancer. (2014) (174)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma (2008) (174)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
Expression of interleukin 10 in human melanoma. (1994) (160)
Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of clark's level for prognostic classification (1995) (160)
Determinants of survival in patients with brain metastases from cutaneous melanoma (2010) (159)
Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow‐up of patients with cutaneous melanoma (2000) (159)
Molecular events in melanoma development and progression. (1998) (158)
“Functional” Surgery in Subungual Melanoma (2003) (157)
Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions (2004) (156)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. (2008) (152)
HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. (2001) (146)
Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. (2012) (145)
Genetic and morphologic features for melanoma classification (2010) (144)
Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. (2017) (143)
Dermoscopic classification of atypical melanocytic nevi (Clark nevi). (2001) (142)
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
Prolonged survival of 2 years or longer for patients with disseminated melanoma (1997) (139)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma (2011) (138)
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. (2009) (137)
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. (2020) (137)
Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood (2003) (136)
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma (2011) (136)
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. (2008) (135)
High response rate after intratumoral treatment with interleukin‐2 (2010) (135)
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis (2012) (131)
Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma (1997) (131)
Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma (2000) (131)
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. (2017) (128)
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (2016) (128)
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. (2007) (128)
Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. (1996) (126)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (126)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (2013) (125)
Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. (2004) (125)
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment (2007) (125)
Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. (2001) (124)
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer (2018) (123)
Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells (2013) (123)
Epidemiology of Skin Cancer: Update 2019. (2020) (123)
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. (2012) (123)
Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions (2004) (122)
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. (2019) (122)
Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients (2003) (119)
The increased expression of Y box‐binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance (2007) (116)
The incidence and mortality of cutaneous melanoma in southern Germany (2006) (115)
β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance (2011) (114)
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study (2019) (113)
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. (2020) (112)
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. (2005) (112)
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. (2013) (111)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
Markers and Relative Risk in a German Population for Developing Malignant Melanoma (1989) (109)
The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. (1992) (108)
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma (2009) (108)
Cathepsin D Is Present in Human Eccrine Sweat and Involved in the Postsecretory Processing of the Antimicrobial Peptide DCD-1L* (2006) (108)
Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy (2005) (107)
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. (2020) (107)
K+ Channels and the Intracellular Calcium Signal in Human Melanoma Cell Proliferation (1996) (106)
Desmoplastic Malignant Melanoma: A Clinicopathologic Analysis of 113 Cases (2008) (104)
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. (2019) (101)
Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. (2006) (100)
Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge (2006) (100)
Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. (2015) (100)
Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. (2017) (99)
Short German guidelines: Malignant melanoma (2008) (99)
The adhesion molecule L1 (CD171) promotes melanoma progression (2006) (99)
Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. (1992) (99)
Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. (2003) (97)
Is head and neck melanoma a distinct entity? A clinical registry‐based comparative study in 5702 patients with melanoma (2006) (95)
Is morphoea caused by Borrelia burgdorferi? A review (2000) (95)
Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut (1994) (93)
Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. (2012) (92)
Continuous long‐term monitoring of UV radiation in professional mountain guides reveals extremely high exposure (2003) (92)
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). (2019) (91)
Risk factors of incident melanocytic nevi: A longitudinal study in a cohort of 1,232 young German children (2005) (91)
Time trends of cutaneous melanoma in Queensland, Australia and Central Europe (2000) (91)
[Position and recommendations of the Malignant Melanoma Committee of the German Society of Dermatology on diagnosis, treatment and after-care of malignant melanoma of the skin. Status 1993/94]. (1994) (90)
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. (2008) (89)
Plasmid DNA- and messenger RNA-based anti-cancer vaccination. (2008) (89)
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. (2018) (88)
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma (2008) (87)
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. (2017) (86)
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) (2001) (85)
Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. (1999) (83)
Intralesional rituximab for cutaneous B‐cell lymphoma (2001) (82)
Incisional biopsy and melanoma prognosis: Facts and controversies. (2010) (82)
Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment (1999) (82)
Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. (2006) (82)
Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry (1998) (81)
Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. (2005) (80)
Growth control of melanoma cells and melanocytes by cytokines. (1995) (80)
Das Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft in den Jahren 1983–1993 Epidemiologische Entwicklungen und aktuelle therapeutische Versorgung des malignen Melanoms der Haut** (1995) (80)
Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. (1990) (78)
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. (2010) (78)
Conventional histology vs. three‐dimensional histology in lentigo maligna melanoma (2006) (77)
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. (2010) (75)
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. (2007) (74)
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (2017) (74)
Development of prognostic factors and survival in cutaneous melanoma over 25 years (2005) (74)
Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients (2018) (74)
Dermatoscopy turns histopathologist's attention to the suspicious area in melanocytic lesions. (2001) (73)
Extreme UV Exposure of Professional Cyclists (2000) (73)
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses (2014) (72)
Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment (2010) (72)
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis☆ (2015) (72)
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
Interferons in dermatology. (1989) (71)
Dermoscopy of tungiasis. (2004) (70)
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. (2008) (69)
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. (2011) (68)
The stepwise two‐photon excited melanin fluorescence is a unique diagnostic tool for the detection of malignant transformation in melanocytes (2011) (67)
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. (2006) (66)
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies (2018) (66)
Overall and site‐specific risk of malignant melanoma associated with nevus counts at different body sites: A multicenter case‐control study of the german central malignant‐melanoma registry (1995) (65)
Therapie Der Hautkrankheiten (1995) (64)
Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. (2004) (64)
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (2014) (64)
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. (2017) (63)
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy (2018) (63)
Effects of interferons and cytokines on melanoma cells. (1993) (62)
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors (2011) (61)
Non-AIDS Associated Kaposi's Sarcoma: Clinical Features and Treatment Outcome (2011) (61)
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype (2018) (61)
Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. (2008) (60)
Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. (1993) (59)
Melanoma of the ear: prognostic factors and surgical strategies (2006) (59)
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo (2016) (59)
Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976–2001 (2007) (58)
Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy (2013) (58)
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (2015) (57)
Value of the clinical history for different users of dermoscopy compared with results of digital image analysis (2004) (57)
Brief S2k guidelines – Cutaneous squamous cell carcinoma (2013) (57)
Brief S2k guidelines – Basal cell carcinoma of the skin (2013) (57)
Treatment of psoriasis with interleukin-10. (1998) (57)
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. (2010) (57)
Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. (2012) (56)
High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera (2016) (56)
Histopathologie der Haut (2003) (56)
Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior (2005) (56)
Costs of the detection of metastases and follow-up examinations in cutaneous melanoma (2009) (56)
S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. (2004) (55)
Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction (2000) (54)
Future perspectives in melanoma research (2016) (54)
Agreement between self-assessment of melanocytic nevi by patients and dermatologic examination. (2000) (54)
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (54)
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. (2006) (54)
Detection of dermcidin-derived peptides in sweat by ProteinChip technology. (2002) (54)
The Dermatoscopic Pattern of Clear-Cell Acanthoma Resembles Psoriasis vulgaris (2001) (53)
Is Sentinel Lymph Node Biopsy of Therapeutic Relevance for Melanoma? (2004) (53)
Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors (2011) (53)
Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry. (1997) (52)
Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription–polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness (2001) (52)
Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? (2000) (52)
The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions (2003) (52)
Bacillus subtilis spore film dosimeters in personal dosimetry for occupational solar ultraviolet exposure (2000) (51)
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators (2020) (51)
Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival (2014) (51)
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? (2010) (50)
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up (2011) (50)
[The sun and malignant melanoma]. (1992) (49)
Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. (1991) (49)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement (2009) (48)
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. (2022) (48)
[Malignant melanoma in German-speaking countries in the 80's. Initial results of the central registry for malignant melanoma of the Germany Society of Dermatology in cooperation with the federal health office]. (1987) (48)
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. (2016) (48)
Professional risk for skin cancer development in male mountain guides – a cross‐sectional study (2009) (47)
Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. (1994) (47)
Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma (2014) (47)
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group (2012) (47)
Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. (1996) (46)
Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. (1997) (46)
A case of classical mycosis fungoides associated with human T‐cell lymphotropic virus type I (1991) (45)
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician (2011) (45)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
Polymorphisms of the BRAF gene predispose males to malignant melanoma (2003) (44)
Time trends in incidence and mortality of cutaneous melanoma in Germany (2019) (44)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (44)
Short German guidelines: Merkel cell carcinoma (2008) (44)
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy (2017) (44)
Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR) (2017) (44)
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma (2020) (43)
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start (2017) (43)
Clinical course and prognostic factors of Merkel cell carcinoma of the skin (2009) (43)
Fibroblast growth factor‐2 but not Mel‐CAM and/or β3 integrin promotes progression of melanocytes to melanoma (2003) (43)
Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma (2004) (43)
Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients (2011) (42)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
Blue light phototherapy of neonatal jaundice does not increase the risk for melanocytic nevus development. (2004) (41)
Personal UV Dosimetry by Bacillus subtilis Spore Films (2000) (41)
High Prevalence of Seborrhoeic Dermatitis on the Face and Scalp in Mountain Guides (2000) (41)
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up, prevention and occupational disease (2020) (41)
Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells (2014) (40)
Production of cytokines by human melanoma cells and melanocytes. (1995) (40)
Incomplete expression of the tyrosinase gene family (tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro. (1995) (40)
Persistent scleredema of Buschke in a diabetic: improvement with high‐dose penicillin (1996) (39)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies (2019) (39)
Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma (2016) (39)
Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? (2001) (39)
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (2020) (39)
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (39)
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study (2021) (38)
S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ (2020) (38)
Processing of Laminin α Chains Generates Peptides Involved in Wound Healing and Host Defense (2014) (38)
Exclusion of BRAFV599E as a melanoma susceptibility mutation (2003) (38)
A fluorometric rapid microassay to identify anti‐proliferative compounds for human melanoma cells in vitro (1991) (38)
Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions—an overview (1993) (38)
Short German guidelines: Dermatofibrosarcoma protuberans (2008) (37)
Therapie des malignen Melanoms im Stadium der Fernmetastasierung (2004) (37)
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib (2014) (37)
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib (2016) (37)
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. (2001) (37)
Short German guidelines: Basal cell carcinoma (2008) (37)
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice (2011) (37)
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. (2019) (37)
Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12‐month study (2016) (37)
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low–normal serum lactate dehydrogenase: ‘The AGENDA trial’ (2014) (36)
The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines (2013) (36)
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis (2019) (36)
Short German guidelines: Squamous cell carcinoma (2008) (36)
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. (2013) (36)
443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. (2015) (36)
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET (2020) (35)
[Cutaneous B cell lymphoma in chronic Borrelia burgdorferi infection. Report of 2 cases and a review of the literature]. (1988) (35)
Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009 (2011) (35)
Change of epidemiological characteristics of malignant melanoma during the years 1962-1972 and 1983-1986 in the Federal Republic of Germany. (1989) (35)
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. (2009) (35)
Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma (1997) (34)
Diagnosis of cutaneous tumors with in vivo confocal laser scanning microscopy (2010) (33)
Variability of dermoscopic features of tungiasis. (2005) (33)
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas (2005) (33)
Application of Argon Plasma Coagulation in Skin Surgery (1998) (33)
Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients (2017) (33)
YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT (2018) (32)
Predictors of the use of sunscreen in dermatological patients in Central Europe. (2000) (32)
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (2011) (32)
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. (2017) (32)
Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. (2017) (32)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. (2014) (32)
Micrometastasis of a Sentinel Lymph Node in Cutaneous Melanoma Is a Significant Prognostic Factor for Disease‐Free Survival, Distant‐Metastasis‐Free Survival, and Overall Survival (2004) (32)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? (2013) (31)
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. (2019) (31)
Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization (2000) (31)
Nodular Scabies Detected by Computed Dermatoscopy (2001) (31)
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. (2018) (30)
Targeting tumor-resident mast cells for effective anti-melanoma immune responses. (2019) (30)
Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns (2019) (30)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses (2010) (30)
The German melanoma registry and environmental risk factors implied. (1993) (30)
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma (2015) (30)
Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms” (2013) (29)
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (2017) (29)
Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma (2005) (29)
Imiquimod in the treatment of extensive recurrent lentigo maligna. (2005) (29)
Kurzleitlinie – Malignes Melanom der Haut (2006) (29)
The many unanswered questions related to the German skin cancer screening programme. (2016) (29)
Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis (2013) (29)
Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. (2010) (29)
Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma. (2013) (29)
CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. (2016) (29)
Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. (2019) (28)
Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). (2002) (28)
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma. (2017) (28)
Elective lymph node dissection in primary malignant melanoma: a matched‐pair analysis (1995) (28)
Correlation with digital dermoscopic images can help dermatopathologists to diagnose equivocal skin tumours (2006) (28)
Does Mountaineering Increase the Incidence of Cutaneous Melanoma? (1999) (28)
Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival (2015) (27)
Recurrent nodules in a periauricular plaque‐type blue nevus with fatal outcome (2012) (27)
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover (2020) (27)
Local interventions for actinic keratosis in organ transplant recipients: a systematic review (2018) (27)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
[Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up]. (2003) (27)
In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival (2014) (27)
[Brief guidelines: malignant melanoma of the skin]. (2006) (27)
[Risk factors for the development of malignant melanoma in West Germany. Results of a multicenter-case control study]. (1990) (26)
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2015) (26)
S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018 (2019) (26)
Surveillance and Follow-up Examinations in Cutaneous Melanoma (2003) (26)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. (2016) (26)
Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies (2019) (26)
UVA-Irradiation Induces Melanoma Invasion via the Enhanced Warburg Effect. (2016) (26)
A rational approach to the follow-up of melanoma patients. (2002) (26)
Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions (2014) (26)
Kaposi's sarcoma: a reevaluation. (1995) (26)
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients (2020) (26)
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. (2022) (26)
[Disappearance of the ozone layer and skin cancer: attempt at risk assessment]. (1993) (26)
Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren (2005) (25)
Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis (2017) (25)
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma (2017) (25)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). (2012) (25)
Solar UV-Protective Properties of Textiles (2000) (25)
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients (2019) (25)
Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden‐Württemberg) (2006) (25)
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. (2011) (25)
Deutsche Leitlinie: Malignes Melanom (2005) (25)
The New American Joint Committee on Cancer staging system for cutaneous melanoma (2002) (25)
[Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow-up and clinical outcome in 31 skin diseases]. (1996) (24)
Cutaneous metastatic angiosarcoma with a lethal outcome, following radiotherapy for a cervical carcinoma (1995) (24)
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? (2018) (24)
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2007) (24)
Risk estimation for malignant transformation of melanocytic nevi. (2004) (24)
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. (2019) (24)
Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos? (2020) (24)
Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. (2001) (24)
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial (2011) (24)
Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma (2014) (23)
S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0 (2017) (23)
[Pregnancy, hormone preparations and malignant melanoma]. (1993) (23)
A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. (2006) (23)
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. (2009) (23)
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma (2012) (23)
Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. (2017) (23)
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. (2021) (23)
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) (23)
Phenotypic characterization and prognostic impact of circulating γδ and αβ T‐cells in metastatic malignant melanoma (2016) (23)
Seasonal patterns in the diagnosis of cutaneous malignant melanoma: analysis of the data of the German Central Malignant Melanoma Registry (1997) (23)
Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour (2013) (23)
RNA isolation from human skin tissues for colorimetric differential display. (1998) (22)
Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. (2011) (22)
S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma (2013) (22)
Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. (1992) (22)
A rapid and sensitive fluorometric microassay for determining cell mediated cytotoxicity to adherent growing cell lines. (1992) (22)
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. (2018) (22)
Mollusca contagiosa bei HIV-Infektion Klinische Manifestation, Beziehung zum Immunstatus und prognostische Wertigkeit bei 39 Patienten (1997) (22)
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy (2018) (22)
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry (2016) (22)
Hyperkeratosis lenticularis perstans (Flegel’s Disease) – Lack of Response to Treatment with Tacalcitol and Calcipotriol (2001) (21)
Noggin blocks invasive growth of murine B16‐F1 melanoma cells in the optic cup of the chick embryo (2008) (21)
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. (2012) (21)
Melanoma staging: facts and controversies. (2010) (21)
Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines (1999) (21)
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study (2017) (21)
BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy (2014) (21)
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. (2022) (21)
Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma (2011) (21)
Growth control of melanocytes and melanoma cells by cytokines (1993) (21)
Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial. (2015) (21)
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma (2019) (21)
Fine needle aspiration in the diagnosis of metastatic melanoma. (2002) (21)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM). (2012) (21)
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group (2008) (21)
Brief S2k guidelines – Dermatofibrosarcoma protuberans (2013) (21)
Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions (2018) (20)
P53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. (1994) (20)
Dermatofibrosarcoma protuberans – An Update (2004) (20)
Direct effects on proliferation, antigen expression and melanin synthesis of cultured normal human melanocytes in response to UVB and UVA light (2003) (20)
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). (2017) (20)
[Risk factors for the development of malignant melanoma and identification of risk groups in German-speaking regions]. (1995) (20)
Melanoma of the Nose: Prognostic Factors, Three‐Dimensional Histology, and Surgical Strategies (2006) (20)
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase (2017) (20)
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL) (2016) (20)
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020? (2020) (20)
Extramammary Paget's Disease: Extended Subclinical Growth Detected Using Three‐Dimensional Histology in Routine Paraffin Procedure and Course of the Disease (2011) (20)
Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. (2001) (19)
Treatment of melanoma. (2008) (19)
Patient acceptance and trust in automated computer‐assisted diagnosis of melanoma with dermatofluoroscopy (2018) (19)
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma (2018) (19)
Akzeptanz und Reliabilität eines elektronischen psychoonkologischen Screenings bei Patientinnen mit Brustkrebs: eine randomisiert-kontrollierte Studie (2013) (19)
Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma? (2001) (19)
Monocytic myeloid-derived suppressor cells in advanced melanoma patients (2014) (19)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). (2014) (19)
Genetically Determined Coincidence of Kaposi Sarcoma and Psoriasis in an HIV‐Negative Patient After Prednisolone Treatment (1991) (19)
Korrelation von Dermatoskopie und Histopathologie bei melanozytären und nichtmelanozytären Hauttumoren (2003) (19)
12-O-tetradecanoylphorbol-13-acetate not only modulates proliferation rates, but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro. (1993) (19)
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. (2016) (18)
[The HLA pattern in Adamantiades-Behçet's disease in Germany. Association of occurrence, clinical symptoms and follow-up in 39 patients]. (1993) (18)
Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy. (1998) (18)
[HIV-associated dermatoses and their prevalence in 456 HIV-infected patients. Relation to immune status and its importance as a diagnostic marker]. (1994) (18)
Non-melanoma skin cancer: new and future synthetic drug treatments (2017) (18)
Intralesional immunotherapy as a strategy to treat melanoma (2016) (18)
Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. (2019) (18)
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells (2018) (18)
Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. (1991) (18)
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients (2020) (18)
Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. (2018) (17)
[Epidemiology of malignant melanoma in West Germany in an international comparison]. (1989) (17)
Distribution of muscarinic receptor subtype M3 in melanomas and their metastases (2008) (17)
A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma (2014) (17)
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. (2010) (17)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. (2013) (17)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. (1990) (17)
Pediatric patients with cutaneous melanoma: A European study (2018) (17)
Improved protection of outdoor workers from solar ultraviolet radiation: position statement (2020) (17)
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
S2k Kurzleitlinie – Plattenepithelkarzinom der Haut (2013) (16)
Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature (2002) (16)
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover (2016) (16)
The mitochondrial DNA common deletion is present in most basal and squamous cell carcinoma samples isolated by laser capture microdissection but generally at reduced rather than increased levels. (2007) (16)
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma (2012) (16)
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
Inflammatory nodules around the axilla: an uncommon localization of orf virus infection (2009) (16)
Elektive Lymphknotendissektion bei primärem malignen Melanom (1996) (16)
Shave-Exzision von melanozytären Nävi der Haut Indikation, Technik, Ergebnisse (2000) (16)
[Malignant melanoma: increase in incidence and mortality in West Germany]. (1986) (16)
Perspectives of cytokine treatment in malignant skin tumors. (1995) (16)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (16)
HIV-associated dermatoses and their prevalence in 456 HIV-infected individuals. Relation to immunological status and diagnostic significance (1994) (16)
Kurzleitlinie: Plattenepithelkarzinom der Haut, der Lippen und der Augenlider (2006) (16)
Alopecia areata Induced by Adjuvant Treatment with Alpha-Interferon in Malignant Melanoma? (2004) (15)
Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro (2005) (15)
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs (2018) (15)
[Shave excision of melanocytic nevi of the skin: indications, technique, results]. (2000) (15)
Increased CCL17 serum levels are associated with improved survival in advanced melanoma (2015) (15)
Fear of cancer progression in patients with stage IA malignant melanoma (2018) (15)
Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion (2020) (15)
Adjuvant therapy for cutaneous melanoma: a systematic review and network meta‐analysis of new therapies (2019) (15)
Kurzleitlinie – Basalzellkarzinom der Haut (2006) (15)
[Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V]. (1998) (15)
Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? (2020) (15)
Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin. (2007) (15)
[Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls]. (1993) (14)
Lack of survival benefit in sentinel lymph node‐positive melanoma with immediate complete lymphadenectomy – a review (2018) (14)
[Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society]. (1997) (14)
Oncogenetics of melanoma: basis for molecular diagnostics and therapy (2011) (14)
Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases (2012) (14)
[Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study]. (2013) (14)
Prävention des malignen Melanoms (1998) (14)
Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. (2019) (14)
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1 (2017) (14)
Kurzleitlinie – Kutanes neuroendokrines Karzinom (Merkelzell‐Karzinom) (2006) (14)
Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas (2021) (14)
Isolation of three stem cell lines from human sacrococcygeal teratomas (2009) (14)
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (2010) (13)
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. (2012) (13)
Standards der histo- pathologischen Diagnose maligner Melanome Empfehlungen der Arbeitsgruppe des Zentralregisters Malignes Melanom der Deutschen Dermatologischen Gesellschaft (1997) (13)
HIV-assoziierte Dermatosen und ihre Prävalenz bei 456 HIV-Infizierten (1994) (13)
The role of radiotherapy in the overall treatment of melanoma. (2013) (13)
Melanoma and other skin tumors (2012) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
results from a randomised, double-blind, phase 3 trial (2016) (13)
Proliferation and morphology of melanoma cells and benign human melanocytes under varying culture conditions. (1993) (13)
Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 (2012) (13)
Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas (2005) (12)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma : Comparison with Regulatory T Cells and NY-ESO-1-or MelanA – Speci fi c T Cells (2014) (12)
Klinik und Histologie des malignen Melanoms (1997) (12)
PI 3 K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo (2017) (12)
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy (2016) (12)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade (2019) (12)
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro. (1994) (12)
Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry (2018) (12)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (12)
Adjuvante Interferon-α-Therapie beim Melanom Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (1998) (11)
Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry (2020) (11)
[Prognostic parameters and surgical strategies for facial melanomas]. (2003) (11)
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial) (2013) (11)
The need for psycho-oncological support for melanoma patients (2017) (11)
Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. (1994) (11)
The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force (2020) (11)
Verlängertes Überleben bei fernmetastasiertem Melanom und der Einfluß von Behandlungen Analyse des Krankheitsverlaufs von 22 Patienten mit einer Überlebenszeit von zwei Jahren und länger (1996) (11)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells (2008) (11)
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study (2015) (11)
Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016 (2016) (11)
S2k Kurzleitlinie – Basalzellkarzinom der Haut (2013) (11)
Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen (2017) (11)
S3‐Leitlinie ,,Diagnostik, Therapie und Nachsorge des Melanoms” – Kurzfassung (2013) (11)
Cytotoxicity of new duplex drugs linking 3′‐C‐ethynylcytidine and 5‐fluor‐2′‐deoxyuridine against human melanoma cells (2012) (11)
The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. (2018) (11)
Genomics of Immunotherapy-Associated Hyperprogressors—Letter (2017) (11)
[Nevus associated malignant melanomas--diagnostic validation and prognosis]. (1991) (11)
Imaging characteristics of cardiac metastases in patients with malignant melanoma (2017) (11)
Langwellige ultraviolette Strahlung (UVA) und Hautkrebs (1994) (11)
[Chemotherapy of malignant melanoma--current status]. (1990) (11)
Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A Systematic Review and Network Meta-analysis. (2021) (11)
Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study (2020) (11)
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP) (2017) (11)
GSTP1 does not modify MC1R effects on melanoma risk (2017) (11)
Diagnostic Performance of a Support Vector Machine for Dermatofluoroscopic Melanoma Recognition: The Results of the Retrospective Clinical Study on 214 Pigmented Skin Lesions (2019) (11)
[Long-wave ultraviolet radiation (UVA) and skin cancer]. (1994) (11)
Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. (1995) (11)
Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C (2017) (11)
Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population‐based claims data analysis (2021) (10)
Lack of activity of betulin‐based Oleogel‐S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo‐controlled double‐blind phase II trial (2015) (10)
Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED) (2019) (10)
A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results (2007) (10)
[Mollusca contagiosa in HIV infection. Clinical manifestation, relation to immune status and prognostic value in 39 patients]. (1997) (10)
Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo (2012) (10)
Absence of merkel cell polyoma virus in cutaneous melanoma (2011) (10)
Melanozytäre Nävi und Melanomrisiko: Leitlinien für die Betreuung und Therapie (1997) (10)
1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
[Borrelia infections of the skin--progress of knowledge since the discovery of Lyme disease]. (1991) (10)
A Novel Role for Relaxin-2 in the Pathogenesis of Primary Varicosis (2012) (10)
Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study (2016) (10)
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. (2019) (10)
Risikofaktoren für die Entwicklung maligner Melanome und Identifikation von Risikopersonen im deutschsprachigen Raum (1995) (10)
Kutanes neuroendokrines Karzinom (Merkelzellkarzinom) (2008) (10)
Immunotherapy in managing metastatic melanoma: which treatment when? (2017) (10)
Kurzleitlinie – Plattenepithelkarzinom der Haut (2008) (10)
[Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V]. (1998) (10)
A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials (2020) (9)
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (9)
Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
Development of a Microsimulation of Melanoma Mortality for Evaluating the Effectiveness of Population-Based Skin Cancer Screening (2015) (9)
Protein kinase inhibitors in melanoma (2013) (9)
Inactivation of ribonucleotide reductase in tumour cells and inhibition of tumour cell growth by p-alkoxyphenols (1997) (9)
Rieg S, Garbe C, Sauer B, Kalbacher H, Schittek BDermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol 151:534-539 (2004) (9)
[Skin cancer in organ transplant patients. Epidemiology and management]. (2010) (9)
Immunotherapy: Combined immunotherapy—a new standard in metastatic melanoma? (2015) (9)
Pitfalls in the characterization of circulating and tissue‐resident human γδ T cells (2020) (9)
Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study) (2016) (9)
Melanocytic nevi (2011) (9)
Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial (2019) (9)
Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences * (2021) (9)
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. (2014) (9)
Borreliosen der Haut- Fortschritte der Kenntnis seit der Entdeckung der Lyme-Krankheit (1991) (8)
Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile (1996) (8)
Die Versorgung des primären Malignen Melanoms der Haut im deutschen Sprachraum in den Jahren 1983 bis 1993 Eine Studie des Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft*,** (1995) (8)
How to use neoadjuvant medical treatment to maximize surgery in melanoma (2018) (8)
Molecular genetic classification of difficult melanocytic tumors (2013) (8)
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. (2020) (8)
Deutsche Leitlinie: Kutane Lymphome (2005) (8)
Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition (2020) (8)
[Local recurrence and metastasis of thin malignant melanomas (less than or equal to 1mm)]. (1989) (8)
Dysplastic nevi-dysplastic nevus syndromes: clinical features and genetic aspects. (1993) (8)
[Early recognition and prevention of skin cancer]. (2009) (8)
[Prognosis-oriented therapy of malignant melanoma. New concepts]. (1986) (8)
Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma (2020) (8)
Cutaneous melanoma: baseline and ongoing laboratory evaluation (2005) (8)
Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). (2015) (8)
Which melanoma patient carries a BRAF-mutation? A comparison of predictive models (2016) (8)
Isotopic response of graftversus host disease following Herpes Zoster infection : case report and review of the literature (2012) (8)
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (8)
Dermatoskopie von Hauttumoren (2003) (8)
[Correlation between dermoscopy and histopathology in pigmented and non-pigmented skin tumours]. (2003) (8)
Psychosoziale Belastung und subjektives Erleben von Melanompatienten in der ambulanten Nachsorge (2004) (8)
Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling. (2016) (8)
Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). (2011) (8)
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy? (2020) (8)
Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study. (2012) (8)
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). (2013) (8)
The impact of the COVID‐19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities (2021) (8)
Deutsche Leitlinie: Basalzellkarzinom (2005) (7)
Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy (2020) (7)
Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement? (2019) (7)
Nested melanoma, a newly defined entity. (2013) (7)
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma (2016) (7)
Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. (2015) (7)
S3‐Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit (2020) (7)
Ultraschalldiagnostik der Haut und Lymphknoten (1999) (7)
Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. (2020) (7)
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition (2021) (7)
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas (2021) (7)
Protein patterns of benign and malignant human melanocytes show consistent changes in gene expression. (1995) (7)
Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma (2018) (7)
Partial Histological Tumor Regression in Primary Melanoma as Protective Factor for Lymph Node Micrometastasis. (2015) (7)
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study (2020) (7)
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial (2022) (7)
[Combination of interferon-alpha with cytostatic drugs: a potentially successful therapeutic approach in metastatic melanoma]. (1992) (7)
Zunehmende Häufigkeit des malignen Melanoms (2000) (7)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (7)
Hauttumoren bei organtransplantierten Patienten (2010) (7)
[Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma]. (2005) (7)
Failure of gadopentetate dimeglumine-enhanced, high-resolution magnetic resonance imaging to differentiate among melanin-containing skin tumors. (1996) (7)
Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells (2018) (6)
Isotopic response of graft versus host disease following herpes zoster infection: case report and review of the literature. (2012) (6)
[Granulocyte colony stimulating factor (G-CSF) in treatment of patients with HIV-associated mucocutaneous Kaposi sarcoma. Successful use in virus and drug-induced leukopenia]. (1992) (6)
Primäre Diagnose, Ausbreitungsdiagnostik und Prognoseschätzung des malignen Melanoms (1996) (6)
Histopathologische Befundung maligner Melanome in Übereinstimmung mit der AJCC‐Klassifikation 2009: Literaturübersicht und Empfehlungen zum praktischen Vorgehen (2011) (6)
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
Dermatologische Rezepturen. Richtig verschreiben – individuell therapieren (2017) (6)
BRAF-Mutationstestung beim metastasierten malignen Melanom (2012) (6)
Multizentrische Retikulohistiozytose und myelodysplastisches Syndrom (1994) (6)
Jodselektive Bildgebung mit Dual Energy Computertomografie zur Verlaufsbeobachtung von Melanommetastasen unter Systemtherapie (2014) (6)
Dermatologische Rezepturen: Schlüssel zur individualisierten topischen Therapie (2005) (6)
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma (2021) (6)
[Therapy of malignant melanoma at the stage of distant metastasis]. (2004) (6)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities (2010) (6)
Identification of genes specifically regulated in melanoma cells: 266 (1993) (6)
Acquired haemophilia mimicking dermatitis artefacta. (2008) (6)
Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. (2021) (6)
Adjuvante Interferon α− Therapie beim Melanom (1998) (6)
New promises in the adjuvant, and palliative treatment of melanoma. (2007) (6)
Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis. (2013) (6)
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors (2021) (6)
Management of primary and metastasized melanoma in Germany in the time period 1976–2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society (2008) (6)
Epidemiologie des malignen Melanoms der Haut im internationalen Vergleich (1986) (6)
Disseminated Malignant Melanoma (1991) (6)
Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer (2020) (6)
Expression of DNA methyltransferase 1 is a hallmark of melanoma, correlates with response to BRAF and MEK inhibition and with proliferation in melanocytic tumors. (2020) (6)
The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. (2013) (6)
DIGITAL IMAGE ANALYSIS OF PIGMENTED LESIONS: THE TUEBINGER MOLE ANALYSER (1999) (5)
Früherkennung und Primärprävention von Hautkrebs (2008) (5)
S1‐Leitlinie Dermatofibrosarcoma protuberans (DFSP) – Update 2018 (2019) (5)
Meeting Report from the Third Global Workshop on Melanoma (2010) (5)
Pembrolizumab‐induced hepatitis: diagnosis and treatment (2017) (5)
[Brief guidelines: Basal cell carcinoma of the skin]. (2006) (5)
Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin inhibits melanoma cell growth, survival and invasion (2007) (5)
Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? (1996) (5)
[The Malignant Melanoma Central Register of the German Society of Dermatology 1983-1993. Epidemiologic developments and current therapeutic management of malignant melanoma of the skin]. (1995) (5)
Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients. (2010) (5)
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries (2020) (5)
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study. (2022) (5)
Malignant melanoma: classification and staging of malignant melanoma. (2006) (5)
Production of cytokines by melanoma cells (1993) (5)
Deutsche Leitlinie: Merkelzellkarzinom (Kutanes neuroendokrines Karzinom) (2005) (5)
Suppression of Casein Kinase 1 α in Melanoma Cells Induces a Switch in β -Catenin Signaling to Promote Metastasis (2010) (5)
Zur Schwierigkeit der sono- graphischen Diagnose von Lymphknotenmetastasen des malignen Melanoms bei protrahiertem Tumorwachstum (1997) (5)
No evidence of viral genomes in whole‐transcriptome sequencing of three melanoma metastases (2011) (5)
Skin Cancer: Basic Science, Clinical Research and Treatment (1995) (5)
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry (2021) (5)
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
Acquired resistance mechanisms to immunotherapy. (2016) (5)
Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry (2019) (5)
[Brief guidelines: squamous cell carcinoma of the skin, lip and eyelids]. (2006) (5)
Auflichtmikroskopie und digitale Bildanalyse pigmentierter Hautveränderungen Tagung am 3. und 4. Dezember 1999 in Tübingen (2000) (5)
Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. (2010) (4)
Combined targeting of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment (2006) (4)
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma (2017) (4)
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2014) (4)
Expression of oxytocin and its receptor in healthy and varicose great saphenous veins. (2012) (4)
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. (2013) (4)
Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'. (2020) (4)
Nachsorge bei Melanompatienten (1997) (4)
Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy (2019) (4)
Photodynamic action of ultraviolet A: induction of cellular hydroperoxides. (1995) (4)
Therapeutische Erfahrungen mit der Extrakorporalen Photopherese Technisches Vorgehen, Überwachung und klinische Ergebnisse bei 41 Hautkranken (1996) (4)
1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. (2014) (4)
Erfahrungen mit der neuen American Joint Committee on Cancer (AJCC)‐Klassifikation des kutanen malignen Melanoms (2005) (4)
Neoadjuvant and adjuvant end-points in health technology assessment in oncology. (2021) (4)
Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach (2020) (4)
Myeloid-derived suppressor cells predict survival of advanced melanoma patients : comparison with regulatory T cells and NY-ESO-1-or MelanA-specific T cells (2013) (4)
Zielgerichtete und immunologische Therapieansätze beim malignen Melanom (2014) (4)
S3‐Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren (2020) (4)
The iris signal: blue periphery, tan collaret and freckles pattern – strong indicators for epidermal skin cancer in South‐Eastern Europe (2018) (4)
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses. (2014) (4)
Not all melanomas are created equal: a review and call for more research into nodular melanoma (2021) (4)
The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma (2015) (4)
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
Kurzleitlinie – Dermatofibrosarcoma protuberans (2006) (4)
The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. (1995) (4)
Limited efficacy of intratumoral IL-2 applied to large melanoma metastases (2014) (4)
[Elective lymph node dissection in primary malignant melanoma]. (1996) (4)
Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up (2017) (4)
Epidemiologie und Risikofaktoren des malignen Melanoms (2004) (4)
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy (2021) (4)
Management kutaner Nebenwirkungen von EGFR‐Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt (2011) (4)
Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma (2021) (4)
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial (2020) (4)
Additional reverse transcription–polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients (2004) (4)
1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma (2022) (3)
Leitlinien und Qualitätssicherung für Diagnose und Therapie des malignen Melanoms (1998) (3)
[Interferon therapy in malignant melanoma]. (1990) (3)
Safety of shortened infusion times for combined ipilimumab and nivolumab (2017) (3)
Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells. (2010) (3)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
Quality assurance in melanoma care: The EU-MELACARE study. (2018) (3)
Role of Elective Lymph Node Dissection in Stage I Malignant Melanoma: Evaluation by Matched Pair Analysis (1995) (3)
[Epiluminescent microscopy and digital image analysis of pigmented skin changes. Meeting 3 and 4 December 1999 in T"ubingen]. (2000) (3)
[Targeted therapies for melanoma]. (2014) (3)
Identification of genes specifically regulated in human melanoma cells (2004) (3)
[Growth inhibition of melanoma cells by interferons in vitro. Similar antiproliferative effects of 100-1000 times lower concentrations of nIFN-beta in comparison with rIFN-alpha-2a]. (1989) (3)
Strahlentherapie des Melanoms (2004) (3)
Role of elective lymph node dissection in stage I malignant melanoma: evaluation by matched pair analysis. (1993) (3)
Lymphknotensonographie führt zur Erstentdeckung von regionären Metastasen bei einem Drittel der Patienten mit Melanom (1998) (3)
Garbe C, Hauschild A, Volkenandt M et al.Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393-399 (2008) (3)
Melanozytäre Nävi und maligne Melanome (2006) (3)
[Increasing incidence of malignant melanoma]. (2000) (3)
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study (2021) (3)
Kutane Plattenepithelkarzinome: Maligne Tumoren mit hoher Mutationslast (2019) (3)
[Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]. (2006) (3)
EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL) (2017) (3)
Differential diagnosis of pigmented skin changes and the treatment of melanoma of the lower genital tract in women (2001) (3)
[Brief guidelines--dermatofibrosarcoma protuberans]. (2006) (3)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
10 Potential of different retinoids to induce cellular differentiation of melanoma cells cultured in vitro (1991) (3)
[BRAF mutation detection in metastatic melanoma]. (2012) (3)
Proteogenomics reveals perturbed signalling networks in Malignant Melanoma Cells Resistant to BRAF inhibition. (2021) (3)
More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs (2016) (3)
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (2011) (3)
[Anti-oncogram-oriented polychemotherapy in metastasizing squamous cell carcinoma of the skin: impressive partial remission]. (1990) (3)
[Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb]. (1988) (3)
Human Mammary Epithelial Cells Senescence Barriers Shown by Long-term Culture of Normal Molecular Distinctions between Stasis and Telomere Attrition (2009) (3)
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). (2016) (3)
[Pigmented nevus of foot soles]. (1994) (3)
New landscape in the treatment of melanoma: a 2012 update (2013) (3)
[Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma]. (1989) (3)
[Pustular arthro-osteitis. Pustulosis palmaris et plantaris with arthritis of the sternoclavicular joint]. (1990) (3)
Interessante Frage: Welche anderen Tumoren werden in der Melanom‐Nachsorge mittels PET‐CT entdeckt? (2016) (3)
[Cutaneous squamous cell carcinoma]. (2020) (3)
Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
Krankheiten des subkutanen Fettgewebes (2002) (2)
[Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group]. (1998) (2)
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. (2018) (2)
Epidemiologie, Prävention und Nachsorge maligner Melanome (2001) (2)
A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI. (2014) (2)
Kutanes Plattenepithelkarzinom (2020) (2)
An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases. (2017) (2)
Diagnosis and treatment of basal cell carcinoma: European consensusebased interdisciplinary guidelines (2019) (2)
9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma (2011) (2)
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (2011) (2)
Melanom der Haut – Fakten und Irrtümer (2015) (2)
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
Darstellung von Hauttumoren und entzündlichen Hautkrankheiten mit hochauflösendem Ultraschall (1999) (2)
Late recurrence of melanoma after 10 years – Is the course of the disease different from early recurrences? (2019) (2)
Recent Epidemiological Trends of Cutaneous Melanoma in Germany, Austria and Switzerland. Results of the Central Malignant Melanoma Registry (1997) (2)
Guideline on Lichen sclerosus (2014) (2)
Entwicklungen von Leitlinien in der Dermatologischen Onkologie (2004) (2)
Follow-up in patients with low-risk cutaneous melanoma: is it worth it? (2014) (2)
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib. (2014) (2)
Overall and site-specific risk of malignant melanoma associated with high nevus counts (1993) (2)
Epidemiologie des Melanoms der Haut (2006) (2)
Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set (2019) (2)
Mitoserate beim primären Melanom: Interobserver‐ und Intraobserver‐Reproduzierbarkeit am HE‐Schnitt und in der Immunhistologie (2016) (2)
Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-α on sensitive human melanoma cells in vitro may result in selection of cells in vitro may results in selection of cells with enhanced markers of malignancy (1990) (2)
'Corrigendum to "Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins" [Eur J Cancer 81 (August 2017) 203-205]'. (2017) (2)
Rapidly progressive metastatic malignant melanoma in an HIV patient with severe immunosuppression and atypical nevus syndrome (1994) (2)
Patterns of sun protection for young children: do we deliver the right sun‐protection messages? (2012) (2)
Differenzialdiagnose pigmentierter Hautveränderungen und Melanombehandlung am unteren Genitaltrakt der Frau (2001) (2)
Kurzleitlinie: Malignes Melanom der Haut (2006) (2)
1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study (2021) (2)
[Erythroderma "en nappes claires" as a marker of metastatic kidney cancer. Lasting, successful treatment with rIFN-alpha-2a]. (1991) (2)
In Reply: Sentinel Lymph Node Biopsy in Melanoma (2011) (2)
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi). (2020) (2)
Perspectives of cytokine treatment (1993) (2)
[Manifestations of the "pretherapeutic phase" of malignant melanoma of the skin in Switzerland 1996-1998]. (2001) (2)
Evaluation of photosensitivity in dabrafenib treated metastatic melanoma patients: Results from a phase IIa study. (2016) (2)
[Management of primary malignant melanoma of the skin in German-speaking countries 1983-1993. A study of the Malignant Melanoma Central Register of the German Society of Dermatology]. (1995) (2)
Sonnenschutz: Was ist zuviel, was ist zuwenig? (2005) (2)
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. (2016) (2)
Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM). (2019) (2)
Ipilimumab with fotemustine in metastatic melanoma. (2012) (2)
Diagnosis and Treatment of Melanoma. European Consensus ⴀbased Interdisciplinary Guideline Developed by the Guideline Subcommittee of the (2012) (2)
Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition (2016) (2)
Therapie des malignen Melanoms... (2004) (2)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
New diagnostic method for lesions with transepidermal melanocytic migration. (2014) (2)
Tumoren der Haut (2010) (2)
Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. (2020) (2)
4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17–19, 1992 (1992) (2)
Increase of melanocytic naevus counts in children during 5 years follow-up and analysis of associated factors: 255 (1996) (2)
Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study. (2019) (2)
Differenzialdiagnose pigmentierter Hautveränderungen und Melanombehandlung am unteren Genitaltrakt der Frau (2000) (2)
Bakterielle Infektionen der Haut (2002) (2)
Development Process of Quality Indicators for the S3-Guideline Melanoma (2013) (2)
Maligne epitheliale Hauttumoren (1997) (2)
Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses (2020) (2)
Physikalische Grundlagen der Dermatoskopie (2003) (2)
7.1 Melanozytäre Nävi als Präkursoren und Risikomarker für das maligne Melanom (2010) (2)
Histologisches Korrelat dermatoskopischer Bilder (2003) (1)
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). (2013) (1)
Melanoma in Children and Teenagers (2020) (1)
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. (2014) (1)
P35 Status quo of the S3 guideline ‘Diagnosis, treatment and follow-up of melanoma’ in Germany (2010) (1)
11 The adjuvant study programme of the dermatologic co-operative oncology group (DeCOG) (1999) (1)
[Sentinel lymph node in melanoma]. (2004) (1)
A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma. (2011) (1)
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors (2020) (1)
22 Final results of two randomized adjuvant trials of DeCOG (2004) (1)
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy (2022) (1)
Risikoadaptierte Nachsorge des malignen Melanoms (2004) (1)
Epidemiologie des malignen Melanoms: Aktueller Stand in der Bundesrepublik Deutschland (1991) (1)
7.2 Klinisches Bild und Histologie des malignen Melanoms der Haut (2010) (1)
Pruritus und Antihistaminika (1995) (1)
Abstract PR-1: AGENDA: Results of a randomized, double‐blind phase III trial of dacarbazine with or without Bcl‐2 targeted therapy (oblimersen) in a biomarker‐defined patient population with advanced melanoma (2009) (1)
Hauttuberkulose einschließlich atypischer Mykobakteriosen und Lepra (2002) (1)
19. Antimicrotubule Agents (2013) (1)
Hepatic hemangioma and hemochromatosis misdiagnosed by MRI as metastatic melanoma (2011) (1)
BRAF mutation testing in melanoma: results from a German observational multicenter study (2018) (1)
Melanozytäre Nävi (2006) (1)
Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response? (2018) (1)
[Epidemiology of malignant melanoma of the skin: an international comparison]. (1985) (1)
1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL. (2014) (1)
Diagnosis and Follow-up of Melanoma - what will change with the new S3 Guideline? (2013) (1)
Acral Lentiginous Melanoma (2018) (1)
Micrographic Surgery Allows Fascia Preservation in Dermatofibrosarcoma Protuberans (2021) (1)
The price of tumor control (2013) (1)
[Multicentric reticulohistiocytosis and myelodysplastic syndrome]. (1994) (1)
12 Adjuvant vindesine and interferon-?? in malignant melanoma (1995) (1)
Synergistic interactions between interferonβ and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro (2005) (1)
Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts (2019) (1)
Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany (2021) (1)
Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
Statement on the Letters to the Editors by Starz and Bahmer (2012) (1)
Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8) (2007) (1)
FRUHERKENNUNG UND PRAVENTION DES MELANOMS (1998) (1)
Toxisch epidermale Nekrolyse bei einem Melanompatienten unter zielgerichteter Therapie mit Encorafenib und Binimetinib (2020) (1)
[Dermatoscopy-30 years after the First Consensus Conference]. (2019) (1)
Diagnostic and prognostic classification of atypical spitzoid tumours based on histology and genomic aberrations: A prospective cohort study with long-term follow-up. (2022) (1)
Früherkennung von Hautkrebs (2002) (1)
Epitheliale Präkanzerosen und Karzinome der Haut (1995) (1)
RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients. (2014) (1)
Variations of the prevalence of melanocytic nevi in melanoma patients and controls: 013 (1997) (1)
FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial (2010) (1)
Palliative Therapie bei metastasiertem malignen Melanom: Eine systematische Übersicht von 41 randomisierten Studien (2003) (1)
Dipeptidyl peptidase II is not a marker for progression in melanoma. (2009) (1)
PET/CT bei Patienten mit Melanom: eine Zweiklassenversorgung? Stand der Versorgung mit PET/CT in der primären Ausbreitungsdiagnostik des Melanoms (2021) (1)
Narben, Keloide, Tätowierungen (1995) (1)
Weltkonferenz zum Melanom in Sydney vom 10.–14. Juni 1997 (1998) (1)
The demand for psycho-oncological support in 820 melanoma patients: What are the determinants for the development of distress? (2017) (1)
[Increased survival in distant melanoma metastasis and the effect of treatments. Analysis of the disease course of patients with a survival of 2 years or more]. (1996) (1)
Nachsorge des malignen Melanoms (2009) (1)
Genetc and morphologic features for melanoma classification: implications for clinical trials (2010) (1)
Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment (2015) (1)
[Ulcero-mutilating acro-osteopathy in hereditary neuropathies. Differential diagnosis and pathogenesis]. (2008) (1)
Schwangerschaft und malignes Melanom (1993) (1)
Ichthyosen und andere Verhornungsstörungen (1995) (1)
FC22 3.0% diclofenac in 2.5% hyaluronic acid inverts the process of cancerous transformation in actinic keratoses and maintains therapeutic response by prolongation of treatment (2010) (1)
Dermatoskopisch sichtbare Strukturen (2003) (1)
The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin sensitize melanoma cells to cisplatin and temozolomide (2006) (1)
7.11 Diagnostik und therapeutisches Vorgehen bei extrakutanem Melanom und unbekanntem Primarius (2010) (1)
The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 (2020) (1)
HIV-Infektion und Kaposi-Sarkom (2002) (1)
Melanozytäre Nävi und Melanom (2016) (1)
Diagnostik von Hauttumoren mittels in vivo konfokaler Laser‐Scanning‐Mikroskopie (2010) (1)
Narben, Keloide und Tätowierungen (2002) (1)
Adjuvante medikamentöse Therapie des Melanoms (2006) (1)
[The difficulty of ultrasound diagnosis of lymph node metastases of malignant melanoma in protracted tumor growth]. (1997) (1)
43nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung e.V. (ADF) (2016) (1)
The Database of the Central Malignant Melanoma Registry of the German Dermatological Society (1996) (1)
Upregulated expression of the Y-box binding protein 1 (YB-1) in melanoma cells enforces melanoma cell proliferation, survival and invasion and increases chemoresistance (2006) (1)
Human papillomavirus in basal cell carcinoma - a pilot study. (2009) (1)
Guideline on Photodynamic Therapy (2014) (1)
Staging and prognostic classification of malignant melanoma (1993) (1)
1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. (2014) (1)
465 Ultraviolet (UV)-A irradiation induces melanoma invasion via enhanced Warburg effect (2016) (1)
Dermatoskopie – 30 Jahre nach der 1. Konsensus-Konferenz (2019) (1)
Melanozytäre Nävi und Melanomvorläufer (2002) (1)
UV-Exposure of Mountain Guides and Ski Instructors- Personal Uv-Dosimetry by Bacillus Subtilis- Pore Films (1999) (1)
Malignes Melanom: Epidemiologie und Risikofaktoren (1993) (1)
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs (2018) (1)
Akne, akneiforme Dermatosen und Rosazea (2002) (1)
Prospective comparative study of two rehabilitation schemes in 2354 patients with malignant melanoma (2011) (1)
Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. (2018) (0)
Cancer esearch or and Stem Cell Biology pression of Casein Kinase 1 α in Melanoma Cells Induces R witch in β-Catenin Signaling to Promote Metastasis (2010) (0)
Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients. (2012) (0)
Erratum / Book Review (2001) (0)
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies. (2021) (0)
One-third of metastatic regional lymph nodes of malignant melanoma were only detected by ultrasound, but not by palpation: 292 (1997) (0)
1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
[Treatment of local pigment spots]. (1996) (0)
Übersicht – Epidemiologie und Ätiologie des kutanen malignen Melanoms (2012) (0)
Therapie mit Epoetin beta: Sicher und effektiv in der Prävention und Behandlung der tumorinduzierten Anämie (2003) (0)
9.3 Kryochirurgie und Lasertherapie (2010) (0)
Future perspectives in melanoma research (2016) (0)
7 Hilfsstoffe Rezepturen Hilfsstoffe (2017) (0)
Kutane Nebenwirkungen neuer Krebsmedikamente (2016) (0)
Efficacy of PD-1 based Immunotherapy after radiological Progress under targeted Therapy in Melanoma (2019) (0)
NY-ESO-1 specific CD4+ Thelper1 cells for immunotherapy of cancer. (2014) (0)
Long-term Findings of 3-Months versus 6-Months Treatment with 3% Diclofenac in 2,5% Hyaluronic Acid in Patients suffering from slight to moderate Actinic Keratoses - a multi-centric Study of the Working Group dermatological Oncology (2011) (0)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (0)
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase (2020) (0)
11.4 Therapie kutaner B-Zell-Lymphome (Cutaneous B-Cell Lymphoma, CBCL) (2010) (0)
Update of the Guideline on Chronic Urticaria (2014) (0)
Die Erythema multiforme-Gruppe (2002) (0)
SYNTHESE VON AMIDINOZIMTSAEUREN UND 3-(AMIDINOPHENYL)-PROPIONSAEUREN (1974) (0)
Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
Hauttuberkulose einschl. atypischer Mykobakteriosen und Lepra (1995) (0)
Molekularbiologischer Nachweis einer Mikrometastasierung an Lymphknotengewebe von Melanompatienten mittels Tyrosinase RT-PCR (1998) (0)
Advanced Dermatoscopy Course (2010) (0)
Notfälle und erste Hilfe in der Dermatologie (2002) (0)
S2k Kurzleitlinie – Dermatofibrosarcoma protuberans (2013) (0)
2.3 Beurteilung von Therapieergebnissen (2010) (0)
10 Kommentierte Rezeptursammlung einschließlich NRF-Rezepturen (III) (2017) (0)
14.4 Rehabilitative Maßnahmen (2010) (0)
[Merkel cell tumor of the skin]. (1997) (0)
Update Sentinel Node Studie (2011) (0)
2.1 Grundlagen der tumorspezifischen Dokumentation in klinischen Studienin der Dermatoonkologie (2010) (0)
Innovative Ganzkörper-Kernspintomographie (GK-MRT) vs. Ganzkörper-Computertomographie (GK-CT) im Staging bei Patienten mit metastasierten malignen Melanom: eine monozentrische prospektive Studie des interdisziplinären Hauttumorzentrums des Universitätsklinikums Tübingen (2004) (0)
Aftercare and Follow-up in malignant Melanoma (2013) (0)
6.7 Antiangiogenese (2010) (0)
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients (2011) (0)
Erkrankungen der Lippen, der Zunge und der Mundhöhle (1995) (0)
7.5 Sentinel-Lymphonodektomie (2010) (0)
11.2 Pseudolymphome (2010) (0)
Metastasierungsmuster von Schleimhautmelanomen: Retrospektive Evaluation von Risikofaktoren, Metastasierungs-Zeitpunkt und Metastasierungs-Lokalisation (2015) (0)
[Cutaneous melanoma]. (2007) (0)
Eine randomisierte, offene Therapiestudie zur Überprüfung der Wirksamkeit und Sicherheit von Imiquimod 5%-Creme bei topischer Anwendung 3-mal wöchentlich über 8 oder 12 Wochen in der Behandlung des soliden Basalzellkarzinoms – Eine Analyse von 28 Patienten (2003) (0)
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (0)
10.3 Kryochirurgie, Lasertherapie und photodynamische Therapie (2010) (0)
6.5 Retinoide (inklusive Bexaroten) (2010) (0)
16.1 Primäre Prävention (2010) (0)
University of Groningen The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node- positive melanoma without the need for completion lymph node dissection Verver, (2020) (0)
Deutsche Leitlinie: Kaposi-Sarkom (2005) (0)
Onkogenetik des Melanoms: Grundlage für molekulare Diagnostik und Therapie (2011) (0)
SYNTHESEN VON 4‐AMIDINOPHENYLBRENZTRAUBENSAEURE (APPA) 2. MITT. (1973) (0)
Ein Vergleich von Ganzkörper- Magnetresonanztomographie und Ganzkörper- Computertomographie zum Staging von Patienten mit malignem Melanom im AJCC Stadium III und IV (2009) (0)
Zur Klassifizierung maligner Melanome nach prognostischen Kriterien (1992) (0)
9.1 Diagnostik (klinisches Bild, Histologie, Dermatoskopie, Fluoreszenzdiagnostik) (2010) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
6.2 Antikörper und Antikörper-targeted Therapie (2010) (0)
High Response Rate After Intratumoral (2010) (0)
Schwangerschaftsdermatosen und ihre Behandlung (1995) (0)
16.2 Sekundäre Prävention (Früherkennungsmaßnahmen, Nävus-Check, Screening) (2010) (0)
Nachsorge des Melanoms – neue Aspekte (2010) (0)
2.2 Bedeutung klinischer Studienin der Dermatoonkologie (2010) (0)
Fehldiagnose von Lebermetastasen eines Melanoms durch MRT bei Leberhämagiomen und Hämochromatose (2011) (0)
Temozolomid in Kombination mit Interferon-α versus Temozolomid alleine bei Patienten mit metastasiertem Melanom – eine randomisierte multizentrische Phase-III-Studie der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (2003) (0)
Aktuelle Therapie des malignen Melanoms (2008) (0)
5.1 Imiquimod (2010) (0)
17.1 Integrierte Versorgung (2010) (0)
14.5 Psychoonkologische Betreuung von Patientenmit Hauttumoren (2010) (0)
5.3 Retinoide (2010) (0)
Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland. (2023) (0)
11.6 Therapie seltener Lymphomentitäten (2010) (0)
10.2 Dermatochirurgie inklusive mikroskopisch kontrollierte Chirurgie (2010) (0)
18.2 Informationen für Fachleute (2010) (0)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (0)
Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and survival. (2014) (0)
Guideline on Lichen sclerosus Developed by the Guideline (2014) (0)
Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study (2011) (0)
Epidemiology of cutaneous melanoma (1996) (0)
Molekulare Diagnose des malignen Melanoms (2000) (0)
10.1 Diagnostik (klinisches Bild und Histopathologie) (2010) (0)
Fear of progression in patients with low-risk malignant melanoma. (2017) (0)
Histopathologie des Melanoms (2006) (0)
12.7 Hautmetastasen viszeraler Tumoren (2010) (0)
Epidemiologie des malignen Melanoms in Zentral-Baden-Württemberg 1976 bis 2003 (2008) (0)
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 (2023) (0)
4 Kosten Kosten Grundlagen Kosten (2017) (0)
Patients' general condition under dacarbazine treatment and antiemetic prophylaxis with tropisetron (1993) (0)
ONKODIN: Onkologie, HÃ¤matologie - Daten und Informationen (2017) (0)
7.14 Therapiemonitoring mit Tumormarkern (2010) (0)
9 Exposure of cultured human melanocytes to tumor promoter 12-O-tetradecanolyphorbol-13-acetate modulates melanocytic proliferation, antigen expression and susceptibility to LAK-cell cytotoxicity (1991) (0)
Seltene Infektionen der Haut (2002) (0)
12.3 Kutane Weichteiltumoren (2010) (0)
Das Risikofaktorenkonzept der koronaren Herzkrankheiten vor dem Hintergrund der sozialhygienischen Erforschung und Bekämpfung der Tuberkulose als Volkskrankheit (1982) (0)
Oberrheinische Arbeitsgemeinschaft für Onkologie (OAO/GTOR/AOR) / Deutsche Krebsgesellschaft e.V. (2003) (0)
Posteriores reversibles Enzephalopathie‐Syndrom bei einem Melanompatienten unter Dabrafenib‐ und Trametinib‐Behandlung nach Immuntherapie (2020) (0)
1 Warum rezeptieren (2005) (0)
13.2 Obligate kutane Paraneoplasien (2010) (0)
Evaluierung der Aufklärungsmaßnahmen zur Prophylaxe des malignen Melanoms (2000) (0)
Adjuvant chemotherapy with DTIC for malignant melanoma: 425 (1997) (0)
Aktuelle Therapie des malignen Melanoms * Moderne Aspekte der Dermato−Onkologie – Dessau 17. März 2007 State of the Art Treatment of Melanoma (2008) (0)
Sexuell übertragbare Krankheiten (2002) (0)
Zytokintherapien bei malignen Hauttumoren (1995) (0)
Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. (2020) (0)
Sekundärprävention von Hauttumoren (2012) (0)
1044P Sequential targeted and immunotherapies in stage IV melanoma (2021) (0)
Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti‐PD‐1 therapy (2022) (0)
Kutane Borreliosen: Erythema chronicum migrans, Lymphadenosis cutis benigna, Acrodermatitis chronica atrophicans (2002) (0)
Prospective center-randomized trial of melanoma surveillance in 3,833 patients: An analysis of the early detection of recurrences (2007) (0)
Früherkennung von Hautkrebs und Screeninguntersuchungen (2016) (0)
Vergleich von CT und 18F-FDG-PET/CT im Rahmen des Therapiemanagements von Patienten mit metastasiertem malignen Melanom – Analyse des Outcome nach 5 Jahren Follow up (2014) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
Abstract 5582: NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen (2010) (0)
Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition (2021) (0)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (0)
Spezifische Hyposensibilisierung bei Typ-I-Allergien (2002) (0)
Kosten und Nutzen der Ausbreitungsdiagnostik beim Melanom (2006) (0)
Nichtinfektiöse granulomatöse Krankheiten (1995) (0)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
Die Rolle des Transkriptionsfaktors YB-1 in der Entstehung und Progression des malignen Melanoms (2003) (0)
12.1 Keratoakanthom (2010) (0)
Merkel-Zell-Tumor (2006) (0)
CD14 + CD11b + HLA-DR/ low MDSCs indirectly impact on the prognosis of late-stage melanoma patients by impairing the frequency and function of NY-ESO-1- and Melan-A-reactive peripheral T cells. (2014) (0)
Effects and use of argon plasma coagulation in dermatology (1998) (0)
Reply to ‘Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma’ (2017) (0)
[Squamous epithelial carcinoma of the skin including the lower lip and eyelids (spinalioma, spinous cell carcinoma). Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e.V]. (1998) (0)
7.12 Diagnostisches und therapeutisches Vorgehen bei malignem Melanom in der Schwangerschaft und im Kindesalter (2010) (0)
Frherkennung verbessern!: Die Inzidenz des malignen Melanoms nimmt rasch zu (2004) (0)
15.1 Übelkeit und Erbrechen (2010) (0)
Development of malignant melanoma in three HIV-infected patients with atypical nevus syndrome (1993) (0)
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial (2023) (0)
Sklerodermie und sklerodermiforme Dermatosen (2002) (0)
10.5 Metastasierte epitheliale Tumoren - Therapieoptionen (2010) (0)
18.3 Informationen für Laien (2010) (0)
Editorial (2008) (0)
5.2 COX-Antagonisten (2010) (0)
5.4 Topische Zytostatika (2010) (0)
[Melanocytic nevi]. (2006) (0)
Patientenakzeptanz und ‐vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie (2018) (0)
1233 POSTER Phase l/lI Study With Trabedersen (AP 12009) Monotherapy for the Treatment of Patients With Advanced Pancreatic Cancer, Malignant Melanoma or Colorectal Carcinoma (2011) (0)
15.5 Depression und Suizidalität (2010) (0)
Pseudolymphome, Prälymphome und Lymphome der Haut (1995) (0)
Zirkulierende Tumor‐DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti‐PD‐1‐Therapie (2022) (0)
12.8 Hauttumoren bei Immunsuppression – Dermatologie bei Organtransplantierten (2010) (0)
5.5 Lokale Kontaktsensibilisierung (2010) (0)
12.2 Merkel-Zell-Karzinom (2010) (0)
8.1 Diagnostik (klinisches Bild, Histologie, Dermatoskopie, Fluoreszenzdiagnostik) (2010) (0)
Senescence induction in human melanoma by the combined action of type II interferon and tumor necrosis factor. (2014) (0)
Molekulargenetische Klassifikation schwieriger melanozytärer Tumoren (2013) (0)
6 Pitfalls in retrospective analysis of data from adjuvant trials (1997) (0)
Viruskrankheiten der Haut und der Schleimhaut (2002) (0)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (0)
P6 Decreased immune defense in patients with metastatic melanoma. Results of a LAK-cell assay on established melanoma cell lines (1991) (0)
[Prevention of malignant melanoma]. (1998) (0)
15.3 Tumoranämie und therapieinduzierte Myelosuppression (2010) (0)
8.2 Dermatochirurgie von In-situ-Karzinomen und desextramammären Morbus Paget (2010) (0)
Hyperhidrose und Schweißdrüsenerkrankungen (2002) (0)
Lupus erythematodes und verwandte Immunopathien einschließlich Überlappungssyndromen (2002) (0)
4.5 Photodynamische Therapie (PDT) (2010) (0)
30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (2021) (0)
[Evaluating health education programs for preventing malignant melanoma]. (2000) (0)
Die Dermatofluoroskopie als Diagnoseverfahren bei verschiedenen pigmentierten Hautläsionen: Stärken und Schwächen (2020) (0)
Safety data on adjuvant treatment of cutaneous melanoma patients with interferon-alpha2b and pegylated interferon-alpha2b: An interim analysis of 285 patients treated in Germany (2016) (0)
6.4 Interleukin 2 (IL-2) (2010) (0)
The delay of melanoma diagnosis and associated factors: results of standardized interviews with 429 patients (1997) (0)
2.5 Medizinisch-ethische Aspekte des Aufklärungsgesprächs mit Patienten über die Teilnahme an einer randomisierten Therapiestudie (2010) (0)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. (2012) (0)
P17 Comparative genomic hybridization (CGH) analysis of a distinct variant of melanocytic nevi, named deep penetrating blue nevi (2010) (0)
SYNTHESE VON AMIDINOMANDELSAEUREN, AMIDINOPHENYL-ALPHA-CHLORESSIGSAEUREN UND AMIDINOPHENYLGLYOXYLSAEUREN (1974) (0)
Factors influencing BRAFV600 mutation testing quality in melanoma: Results from a large, non-interventional, multicenter study in Germany. (2016) (0)
Adjuvant treatment of high risk malignant melanoma stages I—III with IFN-β and vindesine: 123 (1993) (0)
17.3 Zusatzbezeichnung „MedikamentöseTumortherapie“ (2010) (0)
18.1 Einleitung (2010) (0)
Ablagerungsdermatosen, Hautveränderungen bei Stoffwechselstörungen und Mangelsyndromen (2002) (0)
Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives (2016) (0)
Ganzhirnbestrahlung und stereotaktische Bestrahlung bei Patienten mit cerebralen Metastasen des malignen Melanoms: eine retrospektive Studie des interdisziplinären Hauttumorzentrums des Universitätsklinikums Tübingen (2004) (0)
Tropische Infektionen und andere Parasitosen (1995) (0)
Pigmentzellnävi und Melanomvorläufer (1995) (0)
Urtikaria und Nahrungsmittelallergien bzw.-intoleranzen (1995) (0)
TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy (2019) (0)
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
30 years German Dermatologic Cooperative Oncology Group (DeCOG) (2021) (0)
Die UV-Exposition von Radprofis überschreitet deutlich internationale Grenzwerte (2000) (0)
Littoral cell angioma mimicking a splenal metastase in metastatic melanoma (2007) (0)
Malignes Melanom des Viszerum (Primärtumor und Metastasen) (2001) (0)
3.2 Epitheliale Hauttumoren (2010) (0)
Psychoneurotisch bedingte Krankheitszustände der Haut (1995) (0)
Detection of melanoma metastases (1998) (0)
Alterung, Altershaut und kosmetische Dermatologie (2002) (0)
8 Haltbarkeit von Dermatikarezepturen (2005) (0)
PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
Akute follikelgebundene toxische Dermatitis nach Exposition gegenüber polychlorierten Aromaten (1986) (0)
ePOS – elektronisches Psychoonkologisches Screening in Frauenheilkunde und Dermatologie: eine randomisierte kontrollierte Studie (2011) (0)
10.4 Plattenepithelkarzinome der Mundhöhle (2010) (0)
Purpuriforme und hämorrhagische Krankheitsbilder der Haut (1995) (0)
Differential screening for specifically regulated genes in melanoma cells and analysis of their expression (1993) (0)
3 Wie rezeptieren (2005) (0)
Die Prävention des Malignen Melanoms: Beispiele aus Australien und Deutschland (1999) (0)
Kutane Nebenwirkungen der Kombinationstherapie mit Sorafenib und pegyliertem Interferon alfa‐2b bei metastasiertem Melanom (ADO SoraPeg‐Studie) (2013) (0)
Induction of lipid hydroperoxides in cultured human fibroblasts by UVA (1993) (0)
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
6.6 Vakzinierung (2010) (0)
Multicenter study on prognostic factors in 692 patients with brain metastases of malignant melanoma. (2009) (0)
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (0)
Melanozytäre Hauttumoren können mittels der dermatoskopischen Klassifikation von atypischen Nävi gut in ihrer Dignität eingeteilt werden (2003) (0)
11 Weiterführende Literatur (2017) (0)
Erkrankungen des Penis und des Hodens (2002) (0)
Die Parapsoriasisgruppe und Verwandtes (2002) (0)
Review of: "Melanocytic Nevi In Sentinel Lymph Nodes - Association With Cutaneous Nevi And Clinical Relevance In Patients With Cutaneous Melanomas" (2021) (0)
Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) (0)
Von der Dermatoskopie zur digitalen Bildanalyse (2003) (0)
Temozolomide (TMZ) in combination with pegylated interferon alfa-2b for stage IV metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2016) (0)
FC12 Long term follow-up of 72 melanoma patients after intratumoral treatment with interleukin-2: favorable survival and high rate of objective responses upon subsequent chemotherapy (2010) (0)
Früherkennung und Prävention von Hautkrebs Sonnenschutzmittel werden weit ü berschätzt (2009) (0)
Cutaneous Metastases of Melanoma: New Treatment Options (2009) (0)
7.9 Second-Line-Therapie des metastasierten Melanoms (2010) (0)
Adjuvante Therapie mit Interferon-alpha beim malignen Melanom. Ergebnisse einer Meta-Analyse (2004) (0)
4.2 Strahlentherapie (2010) (0)
Systemische Therapie des metastasierten Melanoms (2010) (0)
13.3 Fakultative kutane Paraneoplasien (2010) (0)
Der Kenntnisstand der Dermatologen in Praxis und Klinik zum Melanom: TED-Befragungen während eines Satelliten-Symposiums der DDG-Tagung in Berlin (2002) (0)
SYNTH. VERSCHIEDEN BASISCH SUBSTITUIERTER PHENYLBRENZTRAUBENSAEUREN (1974) (0)
Leukoderm und Vitiligo (1995) (0)
Diagnostic and treatment standards in dermatological oncology (1998) (0)
FV1 High response rate and prolonged survival after intratumor treatment with interleukin-2-Results of a phase-II-study on 51 patients with metastatic melanoma (2009) (0)
Funktionserhaltendes operatives Vorgehen beim akrolentiginösen Melanom (1992) (0)
1.1 Karzinogenese bei kutanen Tumoren (2010) (0)
Antiemetic treatment with tropisetron during polychemotherapy of metastasizing melanoma: 133 (1993) (0)
Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO (2011) (0)
Melanom ? Licht am Ende des Tunnels (2010) (0)
Analysis of Amino Acid Variants in Malignant (2021) (0)
9 Obsolete, bedenkliche und problematische Stoffe (2005) (0)
Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung (2017) (0)
4.3 UV-Therapie (2010) (0)
14.3 Kutane Lymphome (2010) (0)
7.13 Stadienabhängige Staging-Verfahren (2010) (0)
4.6 Lasertherapie inklusive laserinduzierte Thermotherapie (2010) (0)
Mucosal Melanoma (2019) (0)
SYNTHESE VON AMIDINOPHENYLESSIGSAEUREN UND AMIDINOPHENYL-ALPHA-AMINOESSIGSAEUREN (1974) (0)
Dermcidin-α : Green Variant of Dermcidin, Human Antimicrobial Peptide in Sweat† (2002) (0)
Tumordurchmesser – ein prognostischer Faktor bei kutanen Melanomen? (2004) (0)
3.4 Sonstige Tumoren (2010) (0)
2.4 Messung der Lebensqualität (2010) (0)
Berufsdermatosen: Prophylaxe und Therapie im Beruf (1995) (0)
DEVELOPMENT OF MELANOCYTIC NEVI IN CHILDREN. AUTHORS' REPLY (1997) (0)
Peptide a action antimicrobienne (2002) (0)
Chemoimmunotherapy in metastatic melanoma: 410 (1997) (0)
Online‐Konsensuskonferenzen für die Entwicklung und Aktualisierung von Leitlinien für die klinische Praxis: Eine Umfrage unter den Teilnehmenden der deutschen S3‐Leitlinie zur aktinischen Keratose und kutanem Plattenepithelkarzinom (2021) (0)
NAEVUS ASSOCIATED MALIGNANT MELANOMA: AN ENTITY? (1992) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Berufsbedingte Hautschäden und Hautkrebs bei Bergführern (2006) (0)
A case-control study of the associations of PGC1 beta genotype with melanoma, skin reflectance, and naevus count (2016) (0)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
86th Annual Meeting of the Swiss Society for Dermatology and Venereology: Abstracts (2004) (0)
Development of melanocytic nevi in children [1] (multiple letters) (1997) (0)
6 Rezeptierbare Wirkstoffe (2005) (0)
Freie Vorträge (2015) (0)
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies (2018) (0)
Lupus erythematodes und Varianten (einschließlich Überlappungssyndrome) (1995) (0)
11.3 Diagnostik (Histologie, molekulare Genetik) (2010) (0)
Amino Acid Variants in Malignant Melanoma (2020) (0)
3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective (2015) (0)
2.6 Entwicklung evidenzbasierter Leitlinien (2010) (0)
Aphthen und Morbus Behçet (1995) (0)
Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC. (2010) (0)
13.1 Allgemeines (2010) (0)
Prospektive vergleichende Untersuchung zweier Nachsorgeschemata bei 2354 Patienten mit malignem Melanom (2011) (0)
Nagelkrankheiten und ihre Behandlung (1995) (0)
11.1 Klinisches Bild und Klassifikation (2010) (0)
Das Basalzellkarzinom – Diagnostik und Management (2016) (0)
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade (2022) (0)
Behandlung lokaler Pigmentflecke (1996) (0)
11 Kompatibilitätstabellen der pharmazeutischen Industrie und Rezeptur mit Fertigarzneimitteln (2005) (0)
Kurzleitlinie – Dermatofibrosarcoma protuberans (2006) (0)
The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment. (2014) (0)
Metastatic melanoma of unknown primary origin: 277 (1997) (0)
Lichen ruber und lichenoide Dermatosen (2002) (0)
7.4 Chirurgische Therapie des Primärtumors (2010) (0)
8.3 Kryochirurgie und Lasertherapie (2010) (0)
Systemic therapy of melanoma (1994) (0)
Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib (2020) (0)
Sekundärprävention von Hauttumoren nach Organtransplantation (2012) (0)
Intratumoral therapy with interleukin-2 in soft tissue melanoma metastases (2006) (0)
7.8 Medikamentöse Therapie (palliativ) (2010) (0)
Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma. (2023) (0)
86th Annual Meeting of the Swiss Society for Dermatology and Venereology: Title Page / Contents (2004) (0)
Atopie und atopische Dermatitis (2002) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
Abstract 1233: Immunological biomarkers predicting survival in late-stage melanoma patients. (2013) (0)
Pruritus — Antihistaminika und Antiallergica (2002) (0)
Geräte der Dermatoskopie (2003) (0)
9.4 Topische Therapie (2010) (0)
Prognostische Genexpressionstests beim Melanom auf dem Weg in die Routine (2020) (0)
Prävention des malignen Melanoms — Strategien, Ergebnisse und Perspektiven in verschiedenen Ländern (1997) (0)
Lichtdermatosen und Lichtschutz (1995) (0)
Successful treatment of satellite- and intransit-metastases with IFN-β in a case of metastatic melanoma: 326 (1993) (0)
Apoptosis in BRAFV600E Melanoma Cells Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated ` (2013) (0)
14.2 Epitheliale Tumoren und andere Tumorentitäten (2010) (0)
6.3 Interferone (2010) (0)
Abstract 3034:18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs (2018) (0)
697 Assessment of the tolerability, safety and efficacy of increasing doses of peginterferon alfa-2a (40KD) in a randomised study in patients with metastatic malignant melanoma (2003) (0)
Kurzleitlinie: Basalzellkarzinom der Haut (2006) (0)
ABC-point-list of dermoscopy (2004) (0)
Individualised Proteogenomics Applied to Analysis of Amino Acid Variants in Malignant Melanoma (2020) (0)
8.4 Topische Therapie (2010) (0)
Treatment of disseminated malignant melanoma: 023 (1997) (0)
Übersicht - Das maligne Melanom - Epidemiologie, Risikofaktoren, Primärprävention (2009) (0)
Erkrankungen des Knorpels (1995) (0)
15.4 Schmerztherapie in der Dermatoonkologie (2010) (0)
7.3 Bildgebende Diagnostik des Primärtumors (2010) (0)
1055P Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma (2021) (0)
6.1 Grundlagen der systemischen Zytostatikatherapie (2010) (0)
1.2 Mechanismen der Metastasierung (2010) (0)
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib. (2014) (0)
Aphthen und Morbus Adamantiades-Behçet (2002) (0)
Rare Tumors of the Skin and Subcutaneous Tissues (2012) (0)
7.10 Zielgerichtete Therapie (2010) (0)
A first-line, phase II study with dacarbazine (DTIC) plus thymosin alpha 1 (Ta1) with or without interferon alpha (IFNa) vs. DTIC plus IFNa in stage IV melanoma (2006) (0)
1226PDFive-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma (2017) (0)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
Conflicts of interests 2 The Work Under Consideration for Publication (2014) (0)
Oral tropisetron (TRO) in the prophylaxis of dacarbazine (DTIC) induced nausea and emesis (1993) (0)
Development of Melanocytic Nevi in Children-Reply (1997) (0)
Integrin adhesion molecules α2 and β3 are enhanced during melanoma tumor progression and their expression is stimulated by contact to extracellular matrix-proteins: 251 (1993) (0)
[Working Group of Dermatologic Oncology (ADO)]]. (2009) (0)
Analysis of Amino Acid Variants in Malignant Melanoma Cells Resistant to BRAF inhibition (2020) (0)
Racial Impartiality: The Women of the Abolition Movement as Depicted in Dessa Rose and The Invention of Wings (2015) (0)
The Importance of the Gene Locus DHCR24 for the Overall Survival of Melanoma Patients - Results of a genome-wide Association Study (GWAS) (2019) (0)
Supplement II: Abstracts of the international symposium on Skin Carcinogenesis in man and in experimental models. Heidelberg, 29–31 October 1991 (pp S61–S88) (1991) (0)
Das kutane Plattenepithelkarzinom – Frühzeitige Diagnose und Therapie sind entscheidend (2016) (0)
[World conference on melanoma in Sydney 10-14 June 1997]. (1998) (0)
S3-Guideline Diagnosis, Treatment and Care of Melanomas: Methodological Foundations (2010) (0)
Prospective E valuation o f a F ollow-Up S chedule i n C utaneous Melanoma P atients: R ecommendations f or a n E ffective Follow-Up S trategy (2003) (0)
[Oncology guidelines. Editorial]. (2008) (0)
Issue Information (2020) (0)
5 Offizinelle Grundlagen mit Indikationen und Rezepturbeispielen (2005) (0)
Melanome des Ohres – Prognosefaktoren und operative Strategien (2004) (0)
Kein Überlebensvorteil beim Sentinel‐Lymphknoten‐positiven Melanom mit sofortiger kompletter Lymphadenektomie – eine Übersicht (2019) (0)
Veränderungen der klinischen Epidemiologie des malignen Melanoms an der Universitäts-Hautklinik Tübingen 1976-1986 (1990) (0)
Malignant blue naevus of the scalp. (2004) (0)
Casein kinase 1 alpha expression determines beta-catenin protein level and survival of melanoma cells: (2006) (0)
Molekulargenetische Analyse des CDKN2A und des CDK4 Gens bei Patienten mit malignen Melanomen (2006) (0)
Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma (2014) (0)
567 Ultraviolet (UV)-A irradiation induces changes in metabolism which influence, via enhanced Warburg effect, melanoma invasion (2017) (0)
1.3 Genetische Aspekte (2010) (0)
2 Qualitätssicherung bei Verschreibung und Zubereitung (2017) (0)
Dermatosen im Kindesalter (1995) (0)
Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy (2021) (0)
The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective. (2015) (0)
The Prevalence of Human Papillomavirus Genotypes in Nonmelanoma Skin Cancers of Nonimmunosuppressed Individuals Identifies High-Risk Genital Types as Possible Risk Factors 1 (2003) (0)
Früherkennung und Prävention des malignen Melanoms (2009) (0)
Pedikulosis und Skabies (1995) (0)
Jahres-Inhalt 1989, Vol. 12, 1989 (1989) (0)
Seasonal Patterns in the Diagnosis of Cutaneous Malignant Melanoma due to Differential Detection Rather than Biological Causes. An Analysis of the Data of the German Central Malignant Melanoma Registry (1996) (0)
SYNTHESE VON 3-(AMIDINOPHENYL)-ALANINEN UND 3-(AMIDINOPHENYL)-MILCHSAEUREN (1974) (0)
Risk analysis of systemic side effects of tumescent local anaesthesia in the surgical treatment of geriatric and multimorbid patients with skin cancer (2022) (0)
Population-Based Skin Cancer Screening Development of a Microsimulation of Melanoma Mortality for Evaluating the Effectiveness of (2014) (0)
Intradermal intranodal vaccine with Protamin stabilizes mRNA coding for cancer associated antigen - immune response and clinical course in 14 patients with melanoma (2010) (0)
Erkrankungen der Analregion (1995) (0)
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients - The European MelSkinTox study. (2023) (0)
Tumorzellinvasion im dreidimensionalen Hautmodell in vitro (2003) (0)
Guideline on Steroids in Pregnancy (2010) (0)
SYNTHESE EINIGER AMIDINOPHENYLALKYLCARBONSAEUREN MIT C3-, C4- UND C5-SEITENKETTE (1975) (0)
Geographic differences in early detection of cutaneous malignant melanoma in Germany: an analysis of the data of the Central Malignant Melanoma Registry (1996) (0)
12 Weiterführende Literatur (2005) (0)
Multimodale Therapie von Hypophysenadenomen (2015) (0)
Topical Therapy (2020) (0)
17.2 Onkologisch verantwortlicher Arzt (KV) (2010) (0)
Hochrisiko-Melanom: adjuvant Ipilimumab in eskalierter Dosierung (2017) (0)
ANTIMICROBALLY ACTIVE PEPTIDE CROSS-REFERENCES TO RELATED APPLICATIONS (2017) (0)
2 Individualisierung der topischen dermatologischen Behandlung (2005) (0)
6.10 Besonderheiten der medikamentösen Therapiewährend Schwangerschaft und Stillzeit (2010) (0)
Author and Subject Index (2001) (0)
Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a RT-PCR assay in patients with primary cutaneous melanoma (2001) (0)
Eosinophile Dermatosen und Syndrome (1995) (0)
11.5 Therapie kutaner T-Zell-Lymphome (2010) (0)
Theprognosis ofprimary andmetastasising melanoma. Anevaluation of theTNM classification in2,495 patients (1992) (0)
15.2 Inappetenz und Kachexie (2010) (0)
Die neue S3-Leitlinie „Melanom“ (2013) (0)
18.4 Folgen der neuen Informationsmöglichkeiten (2010) (0)
S040 Epidemiology of cutaneous melanoma in Germany (1997) (0)
PET/CT in malignant melanoma: a two‐tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT (2021) (0)
Alterung und Altershaut (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claus Garbe?

Claus Garbe is affiliated with the following schools:

Saarland University
University of Lübeck
James Cook University
ETH Zurich
Kiel University
Aix-Marseille University
University of Tübingen
Technical University of Munich

Claus Garbe's Academic­Influence.com Rankings

Why Is Claus Garbe Influential?

Claus Garbe's Published Works

Published Works

What Schools Are Affiliated With Claus Garbe?

Claus Garbe's AcademicInfluence.com Rankings